Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy.
Breast Cancer Res Treat. 2012 Jul;134(1):277-82. doi: 10.1007/s10549-012-2040-6. Epub 2012 Apr 1.
The aim of this analysis was to investigate the usefulness of Ki-67 labeling index (LI) for the identification of different prognostic subgroups in primary node-negative, triple negative breast cancer (TNBC) patients. From January 1997 to December 2005, 1,053 patients operated for TNBC were identified through the institutional clinical database. The study was performed in accordance with REMARK criteria. The relationship between Ki-67LI and the risk of breast-related deaths was evaluated with a multivariable Cox regression model. Cubic splines were used to model Ki-67LI as a continuous variable. We selected 496 consecutive patients with node-negative TNBC. Median age was 52 years, median Ki-67LI 48% (range 4-95), and median follow up 6 years (range 0.5-13). Total deaths and deaths from BC were 52 (10.5%) and 38 (7.7%), respectively. Ki-67LI increased with decreasing age (P<0.01), increasing tumor size (P<0.01), and grade (P<0.01). When analyzing Ki-67LI as a continuous variable, the risk of death from BC increased steeply with increasing Ki-67LI up to about 35% and remained flat for higher values (adjusted effect of Ki-67 P=0.049; adjusted nonlinear effect P=0.021). Accordingly, when dividing patients into lower (≤35%) and higher (>35%) Ki-67LI subgroups, the 5-year cumulative incidence of breast-related deaths were 2.3 and 9.0%, respectively, with an adjusted HR(>35 vs ≤35) of 2.3 (95% CI 1.0-5.8, P=0.046). Within the group of patients with node-negative TNBC, Ki-67LI was associated with different prognoses subgroups. Ki-67LI might be useful in the design of trials of risk-adapted adjuvant therapies.
本分析旨在探讨 Ki-67 标记指数 (LI) 在识别原发性淋巴结阴性、三阴性乳腺癌 (TNBC) 患者不同预后亚组中的作用。通过机构临床数据库,从 1997 年 1 月至 2005 年 12 月,确定了 1053 例接受 TNBC 手术的患者。本研究符合 REMARK 标准。使用多变量 Cox 回归模型评估 Ki-67LI 与乳腺癌相关死亡风险的关系。立方样条用于将 Ki-67LI 建模为连续变量。我们选择了 496 例连续的淋巴结阴性 TNBC 患者。中位年龄为 52 岁,中位 Ki-67LI 为 48%(范围 4-95),中位随访时间为 6 年(范围 0.5-13)。总死亡人数和乳腺癌死亡人数分别为 52 人(10.5%)和 38 人(7.7%)。Ki-67LI 随年龄降低(P<0.01)、肿瘤大小增加(P<0.01)和分级增加(P<0.01)而增加。当分析 Ki-67LI 作为连续变量时,随着 Ki-67LI 的增加,乳腺癌死亡风险急剧增加,直至约 35%,而对于更高的值则保持平坦(Ki-67 的调整效应 P=0.049;调整后的非线性效应 P=0.021)。因此,当将患者分为 Ki-67LI 较低(≤35%)和较高(>35%)亚组时,5 年累积乳腺癌相关死亡率分别为 2.3%和 9.0%,调整后 HR(>35 vs ≤35)为 2.3(95%CI 1.0-5.8,P=0.046)。在淋巴结阴性 TNBC 患者中,Ki-67LI 与不同的预后亚组相关。Ki-67LI 可能对设计风险适应的辅助治疗试验有用。